Beyond Age and Fitness: Personalized Treatment Selection with Zanubrutinib in Real-World Patients with Chronic Lymphocytic Leukemia — A Case Series, Scoping Review and Expert Survey from the Apulian Hematology Network (REP)
Year: 2026
Type: article
Abstract: To report real-world experience with zanubrutinib, a highly selective second-generation covalent Bruton tyrosine kinase inhibitor (BTKi), in complex CLL patients managed within a regional hematology network; to map the published evidence on zanubrutinib relevant to these scenarios; and to capture how regional experts approach the same clinical questions.
Source: Open Science Framework
Author: Tetiana Skrypets
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225612472
FWCI:
Cites:
Cited by:
Related to: